LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,623 | +50.3% | 42,053 | +79.6% | 0.00% | – |
Q2 2023 | $33,022 | -96.3% | 23,420 | -96.1% | 0.00% | – |
Q1 2023 | $894,666 | +441.4% | 596,444 | +322.3% | 0.00% | – |
Q4 2022 | $165,257 | +334.9% | 141,245 | +315.2% | 0.00% | – |
Q3 2022 | $38,000 | -59.1% | 34,022 | -42.3% | 0.00% | – |
Q2 2022 | $93,000 | -51.3% | 58,977 | -52.5% | 0.00% | – |
Q1 2022 | $191,000 | -74.9% | 124,210 | -60.1% | 0.00% | – |
Q4 2021 | $762,000 | +382.3% | 310,976 | +397.2% | 0.00% | – |
Q3 2021 | $158,000 | -75.7% | 62,549 | -72.6% | 0.00% | – |
Q2 2021 | $650,000 | +291.6% | 228,066 | +223.3% | 0.00% | – |
Q1 2021 | $166,000 | +207.4% | 70,541 | +129.7% | 0.00% | – |
Q4 2020 | $54,000 | -68.6% | 30,715 | -83.3% | 0.00% | – |
Q3 2020 | $172,000 | -80.2% | 183,740 | -81.6% | 0.00% | -100.0% |
Q2 2020 | $867,000 | +452.2% | 996,255 | +424.5% | 0.00% | – |
Q1 2020 | $157,000 | +265.1% | 189,951 | +291.9% | 0.00% | – |
Q4 2019 | $43,000 | +65.4% | 48,468 | +85.2% | 0.00% | – |
Q3 2019 | $26,000 | – | 26,168 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $39,477,000 | 3.01% |
Raffles Associates | 2,080,536 | $2,351,000 | 2.51% |
Defender Capital, LLC. | 5,184,035 | $5,862,000 | 2.30% |
Prescott General Partners LLC | 1,851,851 | $2,093,000 | 0.16% |
DAFNA Capital Management LLC | 140,000 | $158,000 | 0.04% |
Fort Sheridan Advisors LLC | 83,931 | $95,000 | 0.03% |
Long Focus Capital Management, LLC | 215,000 | $243,000 | 0.02% |
XTX Topco Ltd | 72,807 | $82,000 | 0.02% |
Ergoteles LLC | 490,895 | $555,000 | 0.02% |
Beirne Wealth Consulting Services, LLC | 45,000 | $51,000 | 0.02% |